Treatment of Tinea Capitis in Infants
For infants with tinea capitis, oral systemic antifungal therapy is required, with griseofulvin being the only licensed option in the UK for children as young as 1 month old, dosed at 15-20 mg/kg/day for 6-8 weeks. 1
Key Treatment Principles
Topical therapy alone is insufficient for tinea capitis and should not be used as monotherapy, as it cannot penetrate the hair follicle adequately to eradicate infection. 1 Oral systemic therapy is essential to achieve both clinical and mycological cure, prevent scarring, and reduce transmission. 1
First-Line Treatment Selection
The choice of systemic antifungal must be guided by the causative organism or local epidemiology: 1
For Microsporum species (M. canis, M. audouinii):
- Griseofulvin 15-20 mg/kg/day for 6-8 weeks (for infants <50 kg)
- This is the only licensed treatment for tinea capitis in children in the UK and can be used from 1 month of age 1
- Take with fatty food to enhance absorption 1
- Griseofulvin is significantly more effective than terbinafine for Microsporum infections 1
For Trichophyton species (T. tonsurans, T. violaceum, T. soudanense):
- Terbinafine is more efficacious but is NOT licensed for use in infants in the UK 1
- For infants <20 kg: 62.5 mg/day for 2-4 weeks (off-label) 1
- However, given licensing restrictions in infants, griseofulvin remains the safest choice, though higher doses (up to 25 mg/kg/day) and longer duration (12-18 weeks) may be needed for Trichophyton 1
Special Considerations for Infants
Neonates and Very Young Infants:
Recent case reports demonstrate successful treatment in neonates as young as 23-24 days old: 2, 3, 4
- Itraconazole oral solution (5 mg/kg/day continuous therapy or pulse therapy) has shown excellent outcomes in neonatal cases 5, 4
- Some neonatal cases have responded to topical antifungal monotherapy alone with complete resolution 2, 3
- However, these represent exceptional cases, and systemic therapy remains the standard of care
US Practice Patterns:
A 2024 survey of US pediatric dermatologists revealed preference for fluconazole in infants under 2 months, though this is off-label 6
When to Initiate Treatment
Start treatment immediately without waiting for culture results if: 1
- A kerion is present
- Cardinal clinical signs are evident (scaling, lymphadenopathy, alopecia)
- Clinical suspicion is high in high-risk populations
Culture results take 2-4 weeks, and delaying treatment increases transmission risk and potential for scarring.
Adjunctive Measures
Add antifungal shampoo to reduce spore transmission: 1
- Ketoconazole 2% shampoo
- Selenium sulfide 1% shampoo
- Povidone-iodine shampoo
Treatment Failure Management
If no clinical improvement after initial treatment course: 1
- First assess: compliance, drug absorption, reinfection
- If clinical improvement but positive mycology: continue current therapy 2-4 more weeks
- If no improvement: switch to itraconazole (5 mg/kg/day for 2-4 weeks) as second-line 1
Critical Monitoring
- Endpoint is mycological cure, not just clinical improvement 1
- Repeat mycology sampling until clearance is confirmed 1
- Screen and treat family members, especially with T. tonsurans (>50% of family members may be affected) 1
Common Pitfalls to Avoid
- Never use topical therapy alone - this leads to treatment failure
- Don't assume all tinea capitis is the same - Microsporum and Trichophyton require different treatment approaches
- Don't stop at clinical improvement - continue until mycological cure is documented
- For infants, prioritize licensed medications (griseofulvin) over more effective but unlicensed options (terbinafine) unless specialist guidance obtained
- In neonates under 1 month, consider specialist dermatology consultation given limited safety data, though itraconazole pulse therapy shows promise 5, 4